Highlights Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
10.52 ^USD	+0.57%		-4.36%	-27.55%

May. 30	Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial	MT
May. 30	Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial	May. 30	MT
Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes	May. 30	CI
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)	Apr. 01	CI
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219?s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function	Mar. 06	CI
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219	Jan. 08	CI
Biomea Fusion, Inc. Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts	Dec. 09	CI
Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes	Dec. 08	CI
Biomea Fusion Receives Health Canada Clearance for Phase 2 Trial of BMF-219 in Type 1 Diabetes	Dec. 05	MT
Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application for BMF-219 in Type 1 Diabetes	Dec. 05	CI
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease	Nov. 08	CI
Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023	Nov. 02	CI
Biomea Fusion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)	23-10-17	CI
Biomea Fusion Investigational New Drug Application for Diabetes Candidate Approved by FDA	23-10-05	MT
Biomea Fusion Gets FDA, Health Canada Clearance for Expansion Groups in Mid-Stage Diabetes Study	23-09-28	MT
Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study	23-09-28	CI
Biomea Fusion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Highlights

Filters